Abstract: The present invention provide process of preparation of (2R,3S)—N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5(?)-20-epoxy-1,2(?),4,7(?),10(?),13(?)-hexa hydroxy tax-11-en-9-one 4-acetate 2-benzoate or docetaxel and its trihydrate (I)

Abstract: The present invention provide process of preparation of (2R,3S)—N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5(?)-20-epoxy-1,2(?),4,7(?),10(?),13(?)-hexa hydroxy tax-11-en-9-one 4-acetate 2-benzoate or docetaxel and its trihydrate (I)

Abstract: A catalyst composition suitable for conversion of alkanes having 3 to 12 carbon atoms per molecule to aromatic hydrocarbons, wherein the catalyst composition comprises: MN/MA/Ga-zeolite, wherein MN stands for one or more noble metals and MA stands for one or more alkali metals and/or alkaline earth metals. The MN/MA/Ga-zeolite is a zeolite comprising: 0.01-10 wt % of MN with respect to the total MN/MA/Ga-zeolite; 0.01-10 wt % of MA with respect to the total MN/MA/Ga-zeolite; and 0.01-10 wt % Ga with respect to the total MN/MA/Ga-zeolite.

Abstract: The present invention provide processes for the preparation of N-[4-Cyano-3-(trifluoro methyl)phenyl]-3-[(4-fluorophenyl)sulphonyl]-2-hydroxy-2-methyl propanamide (I). The present application also provides a method of purification of N-[4-Cyano-3-(trifluoro methyl)phenyl]-3-[(4-fluorophenyl)sulphonyl]-2-hydroxy-2-methyl propanamide (I) using ethyl acetate solvent resulting in the product, substantially free from process related impurities A, B, C and D. The crystalline product of the process according to the present invention having an XRDP pattern as per FIG. 1, is useful as an active pharmaceutical and has anti-androgenic activity.